NCT04076059 2026-04-17
China ARCHES
Astellas Pharma Inc
Phase 3 Active not recruiting
Clinical Trials
19 trialsNCT06235697 2026-04-14
ASCENDE-SBRT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT02489318 2026-04-13
TITAN
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT03767244 2026-04-13
PROTEUS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04191096 2026-03-20
KEYNOTE-991
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07477626 2026-03-17
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05884398 2026-03-12
LIBERTAS
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06952803 2026-03-10
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
NCT00936390 2026-03-06
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04736199 2026-02-27
ARANOTE
Bayer
Phase 3 Completed
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT00309985 2025-12-11
CHAARTED
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT02799602 2025-12-04
ARASENS
Bayer
Phase 3 Completed
NCT07260435 2025-12-03
Apa/Enza-short
Erasmus Medical Center
Phase 3 Recruiting
NCT06274047 2025-10-30
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT04934722 2025-10-01
KEYNOTE-991
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT06625970 2025-06-26
PEACE 7
UNICANCER
Phase 3 Recruiting